MBX
MBX Biosciences, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$61.72
+0.49%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−23.7x
Market Cap
$2.97B
MomentumView details →
1D Return
+0.49%
YTD Return
+94.51%
RSI (14)
43.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−23.7x
Market Cap
$2.97B
RSI (14)
43.1
MomentumView details →
1D Return
+0.49%
YTD Return
+94.51%
SummaryUpdated Jun 1, 2026
MBX Biosciences, Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Carmel, Indiana. The company specializes in developing precision peptide therapies targeting endocrine and metabolic disorders, with a focus on creating long-acting hormone replacement and metabolic treatments. Since going public in 2000, MBX has built a pipeline of innovative peptide-based drug candidates designed to address unmet medical needs in conditions such as chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity.
Similar companies
Latest newsMore news →
MBX Biosciences dosed the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for adults with hypoparathyroidism, building on positive Phase 2 results and durable one-year clinical benefit.9d agoMBX Biosciences reported a net loss of $37.1 million for Q2 2026, compared to a net loss of $19.4 million in Q2 2025, with cash and marketable securities of $418.6 million as of June 30, 2026.30d agoMBX Biosciences appointed Steve Hoerter as Chairman and CEO, replacing Kent Hawryluk, and appointed John Smither as CFO, effective immediately.53d ago